A Two-Part, Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Hepatic Insufficiency
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Vibegron (Primary)
- Indications Hypertension; Overactive bladder
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 16 Jan 2013 Planned initiation date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.